혈전용해제 시장 : 제품별, 적응증별, 투여 경로별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2023-2032년)

According to a new report published by Allied Market Research, titled, "Clot Busting Drugs Market," The clot busting drugs market was valued at $28.6 billion in 2022, and is estimated to reach $60 billion by 2032, growing at a CAGR of 8.2% from 2023 to 2032.

Clot-busting drugs, also known as thrombolytic agents or fibrinolytic drugs, are medications used to dissolve blood clots in a medical condition called thrombosis. Thrombosis occurs when a blood clot forms within a blood vessel, obstructing the flow of blood. TPA is a thrombolytic or clot buster drug which is used to break up the clot that is causing a blockage or disruption in the flow of blood to the brain and aids in the restoration of blood flow to the affected part of the brain. Anticoagulants, such as heparin, warfarin, dabigatran, apixaban, and rivaroxaban, are medications that thin the blood and help to dissolve blood clots.

Treatment guidelines for cardiovascular disorders frequently need the use of clot-busting medicines in specific conditions.. Improved diagnostic procedures and increased awareness of the signs and symptoms of cardiovascular illnesses have resulted in earlier detection and treatment. To prevent harm in the future, early intervention typically includes the use of clot-busting medications. Overall, the rising prevalence of cardiovascular disorders, combined with innovations in treatment choices and increasing awareness, is boosting demand for clot busting drugs.

Careful and supervised administration is required due to unusual bleeding in the urine or stool, excessive bleeding from wounds or cuts, allergic reactions to clot buster medications, low blood pressure, and other side effects of clot busting medications. There may rarely be other options for controlling blood clots without the use of clot-busting drugs. For instance, in some situations of thrombosis of the deep veins or pulmonary embolism, anticoagulant medications (such as heparin or direct oral anticoagulants) may be used as the primary treatment. The availability of complementary therapies can affect the demand for clot-busting drugs.

The clot busting drugs market expansion is driven by various factors such as economic growth, increase in healthcare coverage, and rise in healthcare awareness. With increased healthcare spending, clot buster medications become more affordable and accessible, resulting in an increase in demand. Ongoing research and clinical trials to assess the efficacy and safety of clot buster medicines boosts the market expansion. As healthcare infrastructure improves and awareness of thrombotic disorders increases in various regions, there is a rising need for effective clot buster drugs. Pharmaceutical companies can tap into these markets by offering affordable and accessible treatment options.

The COVID-19 pandemic has had a substantial impact on many parts of healthcare, including the market for clot busting drugs. While COVID-19 predominantly affects the respiratory system, it can also cause a variety of cardiovascular problems, which may influence the demand for and use of clot-busting medications. COVID-19 has been linked to a higher risk of blood clot formation, which can result in disorders such as deep vein thrombosis (DVT), pulmonary embolism, and stroke. Studies have examined the effectiveness of different anticoagulant treatments, including clot-busting medications, in treating clotting issues associated with COVID-19. These investigations are expected to have an impact on market dynamics and clinical practices in the post-pandemic period.

The key players profiled in this report include: Pfizer Inc., Johnson & Johnson Services Inc, Sanofi, Dr. Reddy's Laboratories, Bayer AG, Boehringer Ingelheim Gmbh, Genentech Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., and Merck & Co.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the clot busting drugs market analysis from 2022 to 2032 to identify the prevailing clot busting drugs market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the clot busting drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global clot busting drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

• Thrombolytic Drugs
• Anti-Platelet Drugs
• Anticoagulants
• Others

By Indication

• Deep Vein Thrombosis
• Atrial Fibrillation
• Others
• Pulmonary Embolism

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • United Arab Emirates
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Bayer AG
• Boehringer Ingelheim Gmbh
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• Genentech Inc.
• Johnson & Johnson Services Inc
• Merck & Co
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities
• 3.5. COVID-19 Impact Analysis on the market
• 3.6. Average Selling Price
• 3.7. Market Share Analysis
• 3.8. Brand Share Analysis
• 3.9. Value Chain Analysis
• 3.10. Key Regulation Analysis
• 3.11. Patent Landscape
• 3.12. Regulatory Guidelines
• 3.13. Trade Data Analysis

CHAPTER 4: CLOT BUSTING DRUGS MARKET, BY PRODUCT

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Thrombolytic Drugs
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Anti-Platelet Drugs
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Anticoagulants
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Others
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country

CHAPTER 5: CLOT BUSTING DRUGS MARKET, BY INDICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Pulmonary Embolism
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Deep Vein Thrombosis
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Atrial Fibrillation
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Others
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Oral
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Injectable
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country

CHAPTER 7: CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 7.1. Overview
  • 7.1.1. Market size and forecast
• 7.2. Hospital Pharmacy
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by region
  • 7.2.3. Market share analysis by country
• 7.3. Online Pharmacy
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by region
  • 7.3.3. Market share analysis by country
• 7.4. Retail Pharmacy
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by region
  • 7.4.3. Market share analysis by country

CHAPTER 8: CLOT BUSTING DRUGS MARKET, BY REGION

• 8.1. Overview
  • 8.1.1. Market size and forecast By Region
• 8.2. North America
  • 8.2.1. Key trends and opportunities
  • 8.2.2. Market size and forecast, by Product
  • 8.2.3. Market size and forecast, by Indication
  • 8.2.4. Market size and forecast, by Route of Administration
  • 8.2.5. Market size and forecast, by Distribution Channel
  • 8.2.6. Market size and forecast, by country
    • 8.2.6.1. U.S.
    • 8.2.6.1.1. Key market trends, growth factors and opportunities
    • 8.2.6.1.2. Market size and forecast, by Product
    • 8.2.6.1.3. Market size and forecast, by Indication
    • 8.2.6.1.4. Market size and forecast, by Route of Administration
    • 8.2.6.1.5. Market size and forecast, by Distribution Channel
    • 8.2.6.2. Canada
    • 8.2.6.2.1. Key market trends, growth factors and opportunities
    • 8.2.6.2.2. Market size and forecast, by Product
    • 8.2.6.2.3. Market size and forecast, by Indication
    • 8.2.6.2.4. Market size and forecast, by Route of Administration
    • 8.2.6.2.5. Market size and forecast, by Distribution Channel
    • 8.2.6.3. Mexico
    • 8.2.6.3.1. Key market trends, growth factors and opportunities
    • 8.2.6.3.2. Market size and forecast, by Product
    • 8.2.6.3.3. Market size and forecast, by Indication
    • 8.2.6.3.4. Market size and forecast, by Route of Administration
    • 8.2.6.3.5. Market size and forecast, by Distribution Channel
• 8.3. Europe
  • 8.3.1. Key trends and opportunities
  • 8.3.2. Market size and forecast, by Product
  • 8.3.3. Market size and forecast, by Indication
  • 8.3.4. Market size and forecast, by Route of Administration
  • 8.3.5. Market size and forecast, by Distribution Channel
  • 8.3.6. Market size and forecast, by country
    • 8.3.6.1. Germany
    • 8.3.6.1.1. Key market trends, growth factors and opportunities
    • 8.3.6.1.2. Market size and forecast, by Product
    • 8.3.6.1.3. Market size and forecast, by Indication
    • 8.3.6.1.4. Market size and forecast, by Route of Administration
    • 8.3.6.1.5. Market size and forecast, by Distribution Channel
    • 8.3.6.2. UK
    • 8.3.6.2.1. Key market trends, growth factors and opportunities
    • 8.3.6.2.2. Market size and forecast, by Product
    • 8.3.6.2.3. Market size and forecast, by Indication
    • 8.3.6.2.4. Market size and forecast, by Route of Administration
    • 8.3.6.2.5. Market size and forecast, by Distribution Channel
    • 8.3.6.3. France
    • 8.3.6.3.1. Key market trends, growth factors and opportunities
    • 8.3.6.3.2. Market size and forecast, by Product
    • 8.3.6.3.3. Market size and forecast, by Indication
    • 8.3.6.3.4. Market size and forecast, by Route of Administration
    • 8.3.6.3.5. Market size and forecast, by Distribution Channel
    • 8.3.6.4. Spain
    • 8.3.6.4.1. Key market trends, growth factors and opportunities
    • 8.3.6.4.2. Market size and forecast, by Product
    • 8.3.6.4.3. Market size and forecast, by Indication
    • 8.3.6.4.4. Market size and forecast, by Route of Administration
    • 8.3.6.4.5. Market size and forecast, by Distribution Channel
    • 8.3.6.5. Italy
    • 8.3.6.5.1. Key market trends, growth factors and opportunities
    • 8.3.6.5.2. Market size and forecast, by Product
    • 8.3.6.5.3. Market size and forecast, by Indication
    • 8.3.6.5.4. Market size and forecast, by Route of Administration
    • 8.3.6.5.5. Market size and forecast, by Distribution Channel
    • 8.3.6.6. Rest of Europe
    • 8.3.6.6.1. Key market trends, growth factors and opportunities
    • 8.3.6.6.2. Market size and forecast, by Product
    • 8.3.6.6.3. Market size and forecast, by Indication
    • 8.3.6.6.4. Market size and forecast, by Route of Administration
    • 8.3.6.6.5. Market size and forecast, by Distribution Channel
• 8.4. Asia-Pacific
  • 8.4.1. Key trends and opportunities
  • 8.4.2. Market size and forecast, by Product
  • 8.4.3. Market size and forecast, by Indication
  • 8.4.4. Market size and forecast, by Route of Administration
  • 8.4.5. Market size and forecast, by Distribution Channel
  • 8.4.6. Market size and forecast, by country
    • 8.4.6.1. China
    • 8.4.6.1.1. Key market trends, growth factors and opportunities
    • 8.4.6.1.2. Market size and forecast, by Product
    • 8.4.6.1.3. Market size and forecast, by Indication
    • 8.4.6.1.4. Market size and forecast, by Route of Administration
    • 8.4.6.1.5. Market size and forecast, by Distribution Channel
    • 8.4.6.2. Japan
    • 8.4.6.2.1. Key market trends, growth factors and opportunities
    • 8.4.6.2.2. Market size and forecast, by Product
    • 8.4.6.2.3. Market size and forecast, by Indication
    • 8.4.6.2.4. Market size and forecast, by Route of Administration
    • 8.4.6.2.5. Market size and forecast, by Distribution Channel
    • 8.4.6.3. India
    • 8.4.6.3.1. Key market trends, growth factors and opportunities
    • 8.4.6.3.2. Market size and forecast, by Product
    • 8.4.6.3.3. Market size and forecast, by Indication
    • 8.4.6.3.4. Market size and forecast, by Route of Administration
    • 8.4.6.3.5. Market size and forecast, by Distribution Channel
    • 8.4.6.4. South Korea
    • 8.4.6.4.1. Key market trends, growth factors and opportunities
    • 8.4.6.4.2. Market size and forecast, by Product
    • 8.4.6.4.3. Market size and forecast, by Indication
    • 8.4.6.4.4. Market size and forecast, by Route of Administration
    • 8.4.6.4.5. Market size and forecast, by Distribution Channel
    • 8.4.6.5. Australia
    • 8.4.6.5.1. Key market trends, growth factors and opportunities
    • 8.4.6.5.2. Market size and forecast, by Product
    • 8.4.6.5.3. Market size and forecast, by Indication
    • 8.4.6.5.4. Market size and forecast, by Route of Administration
    • 8.4.6.5.5. Market size and forecast, by Distribution Channel
    • 8.4.6.6. Rest of Asia-Pacific
    • 8.4.6.6.1. Key market trends, growth factors and opportunities
    • 8.4.6.6.2. Market size and forecast, by Product
    • 8.4.6.6.3. Market size and forecast, by Indication
    • 8.4.6.6.4. Market size and forecast, by Route of Administration
    • 8.4.6.6.5. Market size and forecast, by Distribution Channel
• 8.5. LAMEA
  • 8.5.1. Key trends and opportunities
  • 8.5.2. Market size and forecast, by Product
  • 8.5.3. Market size and forecast, by Indication
  • 8.5.4. Market size and forecast, by Route of Administration
  • 8.5.5. Market size and forecast, by Distribution Channel
  • 8.5.6. Market size and forecast, by country
    • 8.5.6.1. Brazil
    • 8.5.6.1.1. Key market trends, growth factors and opportunities
    • 8.5.6.1.2. Market size and forecast, by Product
    • 8.5.6.1.3. Market size and forecast, by Indication
    • 8.5.6.1.4. Market size and forecast, by Route of Administration
    • 8.5.6.1.5. Market size and forecast, by Distribution Channel
    • 8.5.6.2. Saudi Arabia
    • 8.5.6.2.1. Key market trends, growth factors and opportunities
    • 8.5.6.2.2. Market size and forecast, by Product
    • 8.5.6.2.3. Market size and forecast, by Indication
    • 8.5.6.2.4. Market size and forecast, by Route of Administration
    • 8.5.6.2.5. Market size and forecast, by Distribution Channel
    • 8.5.6.3. United Arab Emirates
    • 8.5.6.3.1. Key market trends, growth factors and opportunities
    • 8.5.6.3.2. Market size and forecast, by Product
    • 8.5.6.3.3. Market size and forecast, by Indication
    • 8.5.6.3.4. Market size and forecast, by Route of Administration
    • 8.5.6.3.5. Market size and forecast, by Distribution Channel
    • 8.5.6.4. South Africa
    • 8.5.6.4.1. Key market trends, growth factors and opportunities
    • 8.5.6.4.2. Market size and forecast, by Product
    • 8.5.6.4.3. Market size and forecast, by Indication
    • 8.5.6.4.4. Market size and forecast, by Route of Administration
    • 8.5.6.4.5. Market size and forecast, by Distribution Channel
    • 8.5.6.5. Rest of LAMEA
    • 8.5.6.5.1. Key market trends, growth factors and opportunities
    • 8.5.6.5.2. Market size and forecast, by Product
    • 8.5.6.5.3. Market size and forecast, by Indication
    • 8.5.6.5.4. Market size and forecast, by Route of Administration
    • 8.5.6.5.5. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top winning strategies
• 9.3. Product Mapping of Top 10 Player
• 9.4. Competitive Dashboard
• 9.5. Competitive Heatmap
• 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

• 10.1. Pfizer Inc.
  • 10.1.1. Company overview
  • 10.1.2. Key Executives
  • 10.1.3. Company snapshot
• 10.2. Johnson & Johnson Services Inc
  • 10.2.1. Company overview
  • 10.2.2. Key Executives
  • 10.2.3. Company snapshot
• 10.3. Sanofi
  • 10.3.1. Company overview
  • 10.3.2. Key Executives
  • 10.3.3. Company snapshot
• 10.4. Dr. Reddy's Laboratories
  • 10.4.1. Company overview
  • 10.4.2. Key Executives
  • 10.4.3. Company snapshot
• 10.5. Bayer AG
  • 10.5.1. Company overview
  • 10.5.2. Key Executives
  • 10.5.3. Company snapshot
• 10.6. Boehringer Ingelheim Gmbh
  • 10.6.1. Company overview
  • 10.6.2. Key Executives
  • 10.6.3. Company snapshot
• 10.7. Genentech Inc.
  • 10.7.1. Company overview
  • 10.7.2. Key Executives
  • 10.7.3. Company snapshot
• 10.8. Eli Lilly and Company
  • 10.8.1. Company overview
  • 10.8.2. Key Executives
  • 10.8.3. Company snapshot
• 10.9. Sun Pharmaceutical Industries Ltd.
  • 10.9.1. Company overview
  • 10.9.2. Key Executives
  • 10.9.3. Company snapshot
• 10.10. Merck & Co
  • 10.10.1. Company overview
  • 10.10.2. Key Executives
  • 10.10.3. Company snapshot